|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
2.99/11.89
|
企業價值
408.11B
|
資產負債 |
每股賬面淨值
3.84
|
現金流量 |
現金流量率
0.05
|
損益表 |
收益
54.32B
|
每股收益
28.42
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/11/01 01:17 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan addedseveral new products and drugs in aesthetics (including Botox). |